MDxHealth SA (MDXH) Price

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 312 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.